Relmada Therapeutics (RLMD) Cash from Financing Activities (2012 - 2026)
Relmada Therapeutics (RLMD) reported Cash from Financing Activities of $156.6 million for Q1 2026, up 67.21% on a QoQ basis from $93.6 million in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Cash from Financing Activities data on file, last reported at $156.6 million in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $156.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $250.0 million (changed N/A YoY) and the FY2025 annual result came in at $93.6 million, up 232034.78% from the prior year.
- Cash from Financing Activities grew to $156.6 million in Q1 2026 per RLMD's latest filing, from $93.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $156.6 million in Q1 2026 and bottomed at -$172487.0 in Q4 2024.
- The 4-year median for Cash from Financing Activities is $569092.0 (2022), against an average of $32.8 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities slumped 99.75%; it then soared 54386.89% in 2025.
- Tracing RLMD's Cash from Financing Activities over 4 years: stood at $409883.0 in 2022, then plunged by 142.08% to -$172487.0 in 2024, then soared by 54386.89% to $93.6 million in 2025, then surged by 67.21% to $156.6 million in 2026.
- Per Business Quant, the three latest RLMD Cash from Financing Activities figures stand at $156.6 million (Q1 2026), $93.6 million (Q4 2025), and -$172487.0 (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 156.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.57 Mn |
| Mar 31, 2026 | 156.57 Mn |
| Dec 31, 2025 | 93.64 Mn |
| Dec 31, 2025 | 93.64 Mn |
| Dec 31, 2024 | -172,487.00 |
| Dec 31, 2024 | -172,487.00 |
| Sep 30, 2024 | -89,601.00 |
| Sep 30, 2024 | -89,601.00 |
| Mar 31, 2024 | 221,747.00 |
| Mar 31, 2024 | 221,747.00 |
| Dec 31, 2022 | 409,883.00 |
| Dec 31, 2022 | 409,883.00 |
| Sep 30, 2022 | 569,092.00 |
| Sep 30, 2022 | 569,092.00 |
| Jun 30, 2022 | 14.09 Mn |
| Jun 30, 2022 | 14.09 Mn |
| Mar 31, 2022 | 29.95 Mn |
| Mar 31, 2022 | 29.95 Mn |
| Dec 31, 2021 | 161.84 Mn |
| Dec 31, 2021 | 161.84 Mn |
| Sep 30, 2021 | 185,156.00 |
| Sep 30, 2021 | 185,156.00 |
| Jun 30, 2021 | 23.99 Mn |
| Jun 30, 2021 | 23.99 Mn |
| Mar 31, 2021 | 1.93 Mn |
| Mar 31, 2021 | 1.93 Mn |
| Dec 31, 2020 | 944,153.00 |
| Dec 31, 2020 | 944,153.00 |
| Sep 30, 2020 | 1.63 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Jun 30, 2020 | 22.89 Mn |
| Jun 30, 2020 | 22.89 Mn |
| Mar 31, 2020 | 3.00 Mn |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2019 | 113.64 Mn |
| Dec 31, 2019 | 113.64 Mn |
| Sep 30, 2019 | 1.17 Mn |
| Sep 30, 2019 | 1.17 Mn |
| Jun 30, 2019 | 12.47 Mn |
| Jun 30, 2019 | 12.47 Mn |
| Mar 31, 2019 | 1.64 Mn |
| Mar 31, 2019 | 1.64 Mn |
| Dec 31, 2018 | -8.63 Mn |
| Dec 31, 2018 | -8.63 Mn |
| Sep 30, 2018 | 319,534.00 |
| Sep 30, 2018 | 319,534.00 |
| Mar 31, 2018 | -56,655.00 |
| Mar 31, 2018 | -56,655.00 |
| Dec 31, 2017 | 2.39 Mn |
| Dec 31, 2017 | 2.39 Mn |
| Sep 30, 2017 | 3.96 Mn |
| Sep 30, 2017 | 3.96 Mn |
| Jun 30, 2017 | -27,583.00 |
| Jun 30, 2017 | -27,583.00 |
| Mar 31, 2017 | -82,450.00 |
| Mar 31, 2017 | -82,450.00 |
| Dec 31, 2016 | -54,403.00 |
| Dec 31, 2016 | -54,403.00 |
| Sep 30, 2016 | -109,234.00 |
| Sep 30, 2016 | -109,234.00 |
| Mar 31, 2016 | -88,533.00 |
| Mar 31, 2016 | -88,533.00 |
| Dec 31, 2015 | -87,915.00 |
| Dec 31, 2015 | -87,915.00 |
| Sep 30, 2015 | -87,304.00 |
| Sep 30, 2015 | -87,304.00 |
| Jun 30, 2015 | 6,250.00 |
| Jun 30, 2015 | 6,250.00 |
| Mar 31, 2015 | -28,089.00 |
| Mar 31, 2015 | -28,089.00 |
| Dec 31, 2014 | 9.02 Mn |
| Dec 31, 2014 | 9.02 Mn |
| Sep 30, 2014 | 4.16 Mn |
| Sep 30, 2014 | 4.16 Mn |
| Jun 30, 2014 | 24.21 Mn |
| Jun 30, 2014 | 24.21 Mn |
| Mar 31, 2014 | 2.76 Mn |
| Mar 31, 2014 | 2.76 Mn |
| May 31, 2012 | 9,500.00 |
| May 31, 2012 | 9,500.00 |